NCT00211068View on ClinicalTrials.gov

A Study of Risk Factors for Anti-erythropoietin Antibody Positive Pure Red Cell Aplasia Among Patients With Chronic Kidney Disease Receiving Epoetin Alfa

CompletedOBSERVATIONAL

Enrollment

124

Participants

Timeline

Start Date

March 31, 2004

Study Completion Date

March 31, 2006

Conditions

Pure Red-cell Aplasia

Interventions

DRUG

No intervention

This study is an observational study. No medication will be provided or administered to the participants. Participants will receive standard-of-care treatment from their individual physicians.

Trial Locations (22)

Unknown

São Paulo

Sorocaba

Bois-Guillaume

Grenoble

Nantes

Orléans

Paris

Tvnsberg

Bloemfontein

Karlshamn

Stockholm

Trollhättan

Vlissingen

Birmingham

Brighton

Bristol

Chelmsford

Edinburgh

London

Manchester

Omagh

Westcliff-on-Sea

All Listed Sponsors

lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

NCT00211068 - A Study of Risk Factors for Anti-erythropoietin Antibody Positive Pure Red Cell Aplasia Among Patients With Chronic Kidney Disease Receiving Epoetin Alfa | Biotech Hunter | Biotech Hunter